Ibrance is indicated for the treatment of patients with hormone receptor positive, human epidermal growth factor receptor 2 negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy; or fulvestrant in patients with disease progression following endocrine therapy.1

Clinical efficacy across patient groups

All subgroups studied​​​​​​​ Visceral disease Bone-only disease Elderly Pre-/peri-menopausal
In 1st line with letrozole
In a post-hoc pooled PFS analysis of PALOMA-1 and PALOMA-2, IBRANCE + letrozole demonstrated PFS improvements vs placebo + letrozole in elderly patients*†2
  • 44% and 40.8% of patients treated with IBRANCE + letrozole were aged ≥65 years in PALOMA-1† and PALOMA-2, respectively3,4

Small patient numbers can be a limitation of subgroup analyses. These analyses are not intended to demonstrate efficacy in particular subgroups.
No adjustments were made for multiple comparisons in the subgroup analyses.

Adapted from Rugo H, et al. 2018.2
Data cut-off dates: November 29, 2013 for PALOMA-1 and February 26, 2016 for PALOMA-2.
*Evaluated according to RECIST Version 1.1.3,4  PALOMA-1 was an open-label, randomised, Phase II study to assess the safety and efficacy of IBRANCE in combination with letrozole as 1st line treatment of patients with ER+/HER2- ABC. The study design of PALOMA-1 is similar to that of PALOMA-2 (PALOMA-2 was double-blind).3

In 1st or later line with fulvestrant

In a post-hoc subgroup analysis of PALOMA-3, IBRANCE + fulvestrant in 1st line or later demonstrated mPFS improvements vs placebo + fulvestrant in elderly patients*2

  • In PALOMA-3, 24.8% of patients treated with IBRANCE + fulvestrant were aged ≥65 years2

These analyses are considered exploratory. No adjustments were made for multiple comparisons in the subgroup analyses. Small patient numbers can be a limitation of subgroup analyses. These analyses are not intended to demonstrate efficacy in particular subgroups.

Adapted from Rugo H, et al. 2018.2
Data cut-off date: October 23, 2015.
*Evaluated according to RECIST Version 1.1.5

ABC = advanced breast cancer; CI = confidence interval; ER+/HER2- = estrogen receptor-positive, human epidermal growth factor receptor 2-negative; FUL = fulvestrant;  HR = hazard ratio; LET = letrozole; mPFS = median progression-free survival; n = number of patients; 
NE = not estimable; PFS = progression-free survival; PLA = placebo; RECIST = Response Evaluation Criteria in Solid Tumors.

References  
  1. IBRANCE® (Palbociclib) Prescribing Information. Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id=12240. Accessed September 17, 2021
  2. Rugo H, et al. Breast Cancer Res Treat. 2019;174(3):719-729.
  3. Finn RS, et al. Lancet Oncol. 2015;16(1):25-35.
  4. Finn RS, et al. N Engl J Med. 2016;375(20):1925-1936.
  5. Cristofanilli M, et al. Lancet Oncol. 2016;17(4):425-439.
​​​​​​​

Support and Services


Learn more ► 
Learn more ► 
Learn more ► 
All rights reserved. Date of preparation: June 2020 PP-IBR-GLB-0254

​​​​​​​Intended for Healthcare Professionals only.

© 2021 Pfizer Pte Ltd. All rights reserved.


The information provided in this site is intended only for Health Care Professionals in Singapore. The products discussed herein may have different product labelling in different countries. Pfizer Corporation Singapore Limited is a subsidiary of Pfizer Inc, a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.